TransMedics Group (TMDX) Misses Q2 EPS by 11c

TransMedics Group (NASDAQ: TMDX) reported Q2 EPS of ($0.39), $0.11 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $8.2 million versus the consensus estimate of $7.8 million.

Cash, cash equivalents and marketable securities were $112.2 million as of June 30, 2021.

For earnings history and earnings-related data on TransMedics Group (TMDX) click here.

You May Also Be Interested In

• KB Home (KBH) Tops Q3 EPS by 16c
• Goldman: 'Our key conclusion is that AI is likely to be credit-positive for banks', 'Rearming Our Overweight Stance on Banks'
• AutoZone (AZO) Tops Q4 EPS by $1.76, Misses on Revenue